Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02673398 · ClinicalTrials.gov registry record · Phase 2
Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT02673398 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT02673398, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects of and how well neratinib works in treating older patients with stage IV HER2-positive breast cancer. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Neratinib
- OTHER Comprehensive Geriatric Assessment
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-12-02 |
| Est. Completion | 2022-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02673398
The ClinicalTrials.gov registry entry for NCT02673398 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02673398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02673398 about?
NCT02673398 is a clinical study titled "Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer". This phase II trial studies the side effects of and how well neratinib works in treating older patients with stage IV HER2-positive breast cancer. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02673398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2016-12-02. Estimated completion is 2022-09-22.
What interventions are being tested in trial NCT02673398?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Neratinib (DRUG), Comprehensive Geriatric Assessment (OTHER), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02673398?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.